Urology

Expert guidance on urologic oncology, stone disease, BPH management, incontinence, and minimally invasive surgical approaches.

Recent Discussions

Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?

1 Answers

Mednet Member

Medical Oncology · Duke University School of Medicine

This is a good question and my general answer is no, as no other ARSI has a phase 3 trial in this nmHSPC setting showing similar benefits. PRESTO was a smaller phase 2 trial of ADT/apalutamide but did not measure or report MFS or OS and was underpowered to look at these endpoints. However if a patie...

Urology

Recent Discussions

Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?

William Catalona, MD

Ralph Clayman, MD

Glenn Preminger, MD

Kirsten Greene, MD

Manoj Monga, MD

Emily Hacker